Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
With the recent FDA approval of neoadjuvant chemotherapy and nivolumab for Stage IB-IIIA NSCLC, does the fact that the study used AJCC 7th edition staging impact your patient selection at all since we currently are using 8th edition staging?
Answer from: Medical Oncologist at Academic Institution
No. The regimen is approved for all tumors greater than 4 cm OR node positive, and broad benefit was observed in all clinical categories.
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
No.